Fingolimod (FTY720) HCl
(Synonyms: 盐酸芬戈莫德; FTY720) 目录号 : GC14807
Fingolimod (FTY720), an immunosuppressant agent, usually used in the treatment of multiple sclerosis, also has anticancer actions and can act as an HDACi (Histone deacetylase inhibitors)[1].
Cas No.:162359-56-0
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >99.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
| Cell experiment [1]: | |
|
Cell lines |
bone marrow derived macrophages |
|
Preparation Method |
BMDMs were stimulated with MSU, GM-CSF/IL-1β or nigericin ± fingolimod (2.5 µM) or febuxostat (200 µM) and UA levels, ROS, XO, and PP2A activities, Xdh (XO) expression and secreted IL-1β levels were determined. |
|
Reaction Conditions |
2.5 µM; 3 h |
|
Applications |
Fingolimod reduced intracellular and secreted UA (catalyzes uric acid) levels, Xdh expression, XO (Xanthine oxidase) activity, ROS (reactive oxygen species) generation and IL-1β secretion, whereas febuxostat enhanced PP2A (Protein phosphatase 2A) activity. |
| Animal experiment [2]: | |
|
Animal models |
C57BL6/J mice |
|
Preparation Method |
Mechanical force-induced HSs were generated in C57BL6/J mice by suturing a dorsal incision and applying a stretching device on Days 6, 8, 10, and 12. On Days 8, 10, and 12, intracutaneous Fingolimod (10 µM) or control vehicle injections were performed. On Day 14, scar tissues and blood were procured and subjected to histology and flow cytometry. |
|
Dosage form |
10 µM; i.c. |
|
Applications |
Flow cytometry showed that Fingolimod decreased the frequencies of macrophages with M2 predominance in the scars but had no effect on total, CD4+, or CD8a+ T cell frequencies. Fingolimod also decreased the vascular endothelial cell frequencies in the scar along with the microvessels, as determined by immunohistochemistry. Compared to the vehicles, Fingolimod treatment significantly reduced the gross scar area and the cross-sectional scar area on histology. On the other hand, Fingolimod tended to reduce white blood cells and significantly reduced the lymphocyte frequencies in the blood. |
|
References: [1] Elsayed S, et al. Protein phosphatase 2A regulates xanthine oxidase-derived ROS production in macrophages and influx of inflammatory monocytes in a murine gout model. Front Pharmacol. 2022 Nov 17;13:1033520. |
|
Fingolimod (FTY720), an immunosuppressant agent, usually used in the treatment of multiple sclerosis, also has anticancer actions and can act as an HDACi (Histone deacetylase inhibitors)[1].
In vitro, Fingolimod at 7.5 or 10 µM, induced a significant reduction in cell viability in D283 and DAOY cultures, also led to a significant increase in the levels of acetylated H3[1]. In vitro, Fingolimod showed cytotoxic antiproliferative effects against androgen-dependent and -independent prostate cancer cells with IC50 ranging from 3.0 ± 0.3 to 6.8 ± 1.7 µM[2]. Jurkat T-lymphocytes exposure to Fingolimod suppressed the amplitude of delayed-rectifier K+ current (IK(DR)) in a time- and concentration-dependent manner with an IC50 value of 1.51 µM[3]. Fingolimod reduced the proliferation and viability of Ph(+) and Ph(-) ALL cell lines and patient samples with IC 50 values for viability between 5.3 to 7.9 µM[4]. Fingolimod differentially suppressed the viability of the OSCC cell lines SCC4, SCC25, and SCC2095 with IC50 values of 6.1, 6.3, and 4.5 µM, respectively[5].
In vivo, E13 C57BL/6 wildtype mice were treated with 1 mg/kg significantly increased the survival of DCX+ neurons in the DG (dentate gyrus) and the SVZ (the subventricular zone) 4 weeks after irradiation as well as a slight increase of proliferating cells[6]. In vivo, 5xFAD mice were treated with 1 mg/kg/day fingolimod decreased both peripheral blood lymphocyte counts and brain Aβ levels, but treated with 0.03 mg/kg/day improved memory, decreased activation of brain microglia and astrocytes, and restored hippocampal levels of GABA and glycerophosphocholine with no effect on circulating lymphocyte counts[7]. In vivo, C57BL/6JOlaHsd mice were treated with 0.5 mg/kg fingolimod increased lesion size (stroke) but decreased ipsilateral brain atrophy in younger mice, without an effect on behavioural outcomes[8].
芬戈莫德(FTY720)是一种免疫抑制剂,通常用于治疗多发性硬化症,也有抗癌作用,可以作为HDACi(组蛋白脱乙酰酶抑制剂)[1]。
在体外,在7.5或10µM时,芬戈莫德诱导D283和DAOY培养物中的细胞活力明显下降,还导致乙酰化H3的水平明显增加[1]。在体外,Fingolimod对雄性激素依赖性和非依赖性前列腺癌细胞显示出细胞毒性抗增殖作用,IC50范围为3.0±0.3至6.8±1.7 µM[2]。Jurkat T淋巴细胞接触Fingolimod后,以时间和浓度依赖的方式抑制延迟整流K+ 电流(IK(DR))的振幅,IC50值为1.51 µM[3]。Fingolimod降低了Ph(+)和Ph(-)ALL细胞系和患者样本的增殖和生存能力,其生存能力的IC50值在5.3至7.9 µM之间[4] 。Fingolimod对OSCC细胞系SCC4、SCC25和SCC2095的生存能力有不同程度的抑制,IC50值分别为6.1、6.3和4.5 µM[5]。
体内试验表明,E13 C57BL/6野生型小鼠在照射4周后,用1 mg/kg的剂量处理,可明显提高DG(齿状回)和SVZ(室下区)中DCX+神经元的存活率,同时增殖细胞也有轻微增加[6]。在体内,5xFAD小鼠接受1 mg/kg/day的芬戈莫德治疗后,外周血淋巴细胞计数和大脑Aβ 水平均下降,但接受0.03 mg/kg/day的治疗后,记忆力得到改善,大脑小胶质细胞和星形胶质细胞的激活减少,海马的GABA和甘油磷酸胆碱水平恢复,对循环淋巴细胞计数没有影响[7]。在体内,C57BL/6JOlaHsd小鼠接受0.5 mg/kg芬戈莫德治疗后,病变大小(中风)增加,但同侧脑萎缩减少,对行为结果没有影响[8]。
References:
[1] Perla AS, et al. Fingolimod (Fingolimod) reduces viability and survival and increases histone H3 acetylation in medulloblastoma cells. Pediatr Hematol Oncol. 2020 Mar;37(2):170-175.
[2] Allam RM, et al. Fingolimod interrupts the cross talk between estrogen metabolism and sphingolipid metabolism within prostate cancer cells. Toxicol Lett. 2018 Jul;291:77-85.
[3] Chang WT, et al. Actions of Fingolimod (Fingolimod), a Sphingosine-1-Phosphate Receptor Modulator, on Delayed-Rectifier K+ Current and Intermediate-Conductance Ca2+-Activated K+ Channel in Jurkat T-Lymphocytes. Molecules. 2020 Oct 2;25(19):4525.
[4] Wallington-Beddoe CT, et al. Fingolimod produces caspase-independent cell death of acute lymphoblastic leukemia cells. Autophagy. 2011 Jul;7(7):707-15.
[5] Bai LY, et al. Fingolimod Induces Autophagy-Associated Apoptosis in Human Oral Squamous Carcinoma Cells, in Part, through a Reactive Oxygen Species/Mcl-1-Dependent Mechanism. Sci Rep. 2017 Jul 17;7(1):5600.
[6] Metzdorf J, et al. Fingolimod for Irradiation-Induced Neurodegeneration. Front Neurosci. 2019 Jul 9;13:699.
[7] Carreras I, et al. Dual dose-dependent effects of fingolimod in a mouse model of Alzheimer's disease. Sci Rep. 2019 Jul 29;9(1):10972.
[8] Diaz Diaz AC, et al. Preclinical Evaluation of Fingolimod in Rodent Models of Stroke With Age or Atherosclerosis as Comorbidities. Front Pharmacol. 2022 Jul 13;13:920449.
| Cas No. | 162359-56-0 | SDF | |
| 别名 | 盐酸芬戈莫德; FTY720 | ||
| 化学名 | 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol;hydrochloride | ||
| Canonical SMILES | CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N.Cl | ||
| 分子式 | C19H34ClNO2 | 分子量 | 343.94 |
| 溶解度 | DMSO : ≥ 100 mg/mL; Water : 50 mg/mL | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.9075 mL | 14.5374 mL | 29.0748 mL |
| 5 mM | 0.5815 mL | 2.9075 mL | 5.815 mL |
| 10 mM | 0.2907 mL | 1.4537 mL | 2.9075 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。